Iodixanol pegol

Drug Profile

Iodixanol pegol

Alternative Names: Iodixanol pegol nanoparticles - Marval Pharma; NCTX; PEGylated liposomal iodixanol injection - Marval Pharma

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marval Pharma
  • Class Contrast media; Polyethylene glycols; Triiodobenzoic acids
  • Mechanism of Action Emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Cancer; Cardiovascular disorders

Most Recent Events

  • 09 Oct 2014 Marval Pharma terminates a phase I trial in Healthy volunteers in USA (NCT02063594)
  • 06 Mar 2014 Phase-I clinical trials in Cancer and Cardiovascular disorders and Atherosclerosis (diagnosis; in volunteers) in USA (IV) (NCT02063594)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top